Disease · HP_0040270
Impaired glucose tolerance
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. Impaired glucose tolerance. Diseases, record HP_0040270. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0040270
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Impaired glucose tolerance
- Open Targets ID
- HP_0040270
- Other names
- Decreased glucose tolerance, Glucose tolerance decreased
- Highest stage of its drugs
- Phase 3, for 8 of its 59 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs59
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| METFORMIN | CHEMBL1431 | Small molecule | Phase 3 | ClinicalTrials.gov | 9 | 9 | 9 | Drugs and targets |
| EMPAGLIFLOZIN | CHEMBL2107830 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ELEXACAFTOR | CHEMBL4298128 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| IVACAFTOR | CHEMBL2010601 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LINAGLIPTIN | CHEMBL237500 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MIFEPRISTONE | CHEMBL1276308 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RELACORILANT | CHEMBL4068611 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TEZACAFTOR | CHEMBL3544914 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SALSALATE | CHEMBL154111 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| THYMOQUINONE | CHEMBL1672002 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 59
See all 59 drugsTargets90
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| GLP1R | Glucagon-like peptide 1 receptor | 4 | Glucagon-like peptide 1 receptor agonist; Glucagon-like peptide 1 receptor antagonist | Phase 2 | https://conductscience.org/library/genes/2740 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 4 | Glucocorticoid receptor agonist; Glucocorticoid receptor antagonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| CFTR | Cystic fibrosis transmembrane conductance regulator | 3 | Cystic fibrosis transmembrane conductance regulator activator; Cystic fibrosis transmembrane conductance regulator positive modulator | Phase 3 | https://conductscience.org/library/genes/1080 | Drugs and targets |
| DPP4 | Dipeptidyl peptidase 4 | 3 | Dipeptidyl peptidase IV inhibitor | Phase 3 | https://conductscience.org/library/genes/1803 | Drugs and targets |
| INSR | Insulin receptor | 3 | Insulin receptor agonist | Phase 1 | https://conductscience.org/library/genes/3643 | Drugs and targets |
| IFNAR1 | Interferon alpha/beta receptor | 2 | Interferon alpha/beta receptor agonist | Unknown | https://conductscience.org/library/genes/3454 | Drugs and targets |
| IFNAR2 | Interferon alpha/beta receptor | 2 | Interferon alpha/beta receptor agonist | Unknown | https://conductscience.org/library/genes/3455 | Drugs and targets |
| PGR | Progesterone receptor | 2 | Progesterone receptor agonist; Progesterone receptor antagonist | Phase 3 | https://conductscience.org/library/genes/5241 | Drugs and targets |
| PPARA | Peroxisome proliferator-activated receptor alpha | 2 | Peroxisome proliferator-activated receptor alpha agonist | Phase 2 | https://conductscience.org/library/genes/5465 | Drugs and targets |
| PPARG | Peroxisome proliferator-activated receptor gamma | 2 | Peroxisome proliferator-activated receptor gamma agonist | Phase 2 | https://conductscience.org/library/genes/5468 | Drugs and targets |
1 to 10 of 90
See all 90 targetsTrials53
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01068860 | To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies | Phase 2 | 246 | 2011-09-05 | Type 2 Diabetes Mellitus, Impaired Glucose Tolerance | CANAKINUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01405911 | Dose Response Finding Study of MK-0431/ONO-5435 in Japanese Subjects With Impaired Glucose Tolerance (MK-0431-105) | Phase 2 | 242 | 2019-12-26 | Glucose Intolerance | SITAGLIPTIN | Its record names the disease | ClinicalTrials.gov |
| NCT00001723 | Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases | Phase 2 | 200 | 2012-12-18 | Diabetes Mellitus, Hypertension, Metabolic Disease, Obesity, Sleep Apnea Syndrome | ORLISTAT | Its record names the disease | ClinicalTrials.gov |
| NCT00995930 | Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients | Phase 2 | 189 | 2015-03-06 | Diabetes Mellitus, Type 2, Atherosclerosis, Prediabetic State | CANAKINUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00500370 | A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients | Phase 2 | 163 | 2009-09-04 | Obesity | EXENATIDE | Its record names the disease | ClinicalTrials.gov |
| NCT03697109 | A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome | Phase 3 | 152 | 2025-04-24 | Cushing Syndrome | RELACORILANT | Its record names the disease | ClinicalTrials.gov |
| NCT01248364 | A Study to Determine Acute (After First Dose) and Chronic (After 28 Days) Effects of Empagliflozin (BI 10773) on Pre and Postprandial Glucose Homeostasis in Patients With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus and Healthy Subjects | Phase 2 | 91 | 2014-09-09 | Diabetes Mellitus, Type 2 | EMPAGLIFLOZIN | Its record names the disease | ClinicalTrials.gov |
| NCT00330733 | Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk | Phase 2/3 | 71 | 2014-04-22 | Atherosclerosis, Cardiovascular Disease, Inflammation, Insulin Resistance, Noninsulin-dependent Diabetes Mellitus | SALSALATE | Its record names the disease | ClinicalTrials.gov |
| NCT04599465 | A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF) | Phase 3 | 69 | 2023-08-03 | Cystic Fibrosis | ELEXACAFTOR, IVACAFTOR, TEZACAFTOR | Its record names the disease | ClinicalTrials.gov |
| NCT00871871 | Multiple Dose Effects of Hydrochlorothiazide and Isosorbide Mononitrate on Glucose Homeostasis (MK-0000-117)(Completed) | Phase 1 | 64 | 2011-09-22 | Hypertension | HYDROCHLOROTHIAZIDE, ISOSORBIDE MONONITRATE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 53
See all 53 trialsComparisons in its trials15
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Orlistat vs Placebo: serious adverse events | 0 of 100 | 2 of 100 | 200 | NCT00001723 | Trial comparisons |
| ACZ885 150mg vs Placebo: serious adverse events | 25 of 95 | 14 of 94 | 189 | NCT00995930 | Trial comparisons |
| Group A (Exenatide) vs Group B (Placebo): serious adverse events | 0 of 73 | 0 of 79 | 152 | NCT00500370 | Trial comparisons |
| Group A (Exenatide) vs Group B (Placebo): Incidence of Patients That Demonstrate Overt Signs of Diabetes Mellitus Diagnosis | 3 of 65 | 2 of 65 | 130 | NCT00500370 | Trial comparisons |
| Salsalate Therapy vs Placebo: serious adverse events | 0 of 34 | 0 of 36 | 70 | NCT00330733 | Trial comparisons |
| Pioglitazone vs Pioglitazone + Exercise Training: serious adverse events | 0 of 20 | 0 of 19 | 39 | NCT00639457 | Trial comparisons |
| Group A (Exenatide) vs Group B (Placebo): Incidence of Patients That Demonstrate Normalization of Impaired Fasting Glucose (IFG) and/or Impaired Glucose Tolerance (IGT) | 13 of 17 | 9 of 16 | 33 | NCT00500370 | Trial comparisons |
| Fenofibrate 145mg PO QD vs Fenofibrate 145 mg PO QD and Pioglitazone 45 mg PO QD: serious adverse events | 0 of 15 | 0 of 12 | 27 | NCT00470262 | Trial comparisons |
| Sitagliptin vs Placebo: deaths from any cause | 0 of 13 | 0 of 13 | 26 | NCT01879228 | Trial comparisons |
| Sitagliptin vs Placebo: serious adverse events | 0 of 13 | 0 of 13 | 26 | NCT01879228 | Trial comparisons |
1 to 10 of 15
See all 15 comparisons in its trialsPapers from its trials38
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0040270
GET https://conductscience.org/api/diseases/v1/HP_0040270/drugs?page=2